JP6818551B2 - Ｃｍｖワクチン - Google Patents

Ｃｍｖワクチン Download PDF

Info

Publication number
JP6818551B2
JP6818551B2 JP2016536893A JP2016536893A JP6818551B2 JP 6818551 B2 JP6818551 B2 JP 6818551B2 JP 2016536893 A JP2016536893 A JP 2016536893A JP 2016536893 A JP2016536893 A JP 2016536893A JP 6818551 B2 JP6818551 B2 JP 6818551B2
Authority
JP
Japan
Prior art keywords
cmv
glycoprotein
arenavirus
seq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016536893A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503482A5 (enExample
JP2017503482A (ja
Inventor
オルリンゲル クラウス
オルリンゲル クラウス
リングナウ カレン
リングナウ カレン
モナス トーマス
モナス トーマス
グイラクホオ ファルシャド
グイラクホオ ファルシャド
フフルマンン ゲルハルド
フフルマンン ゲルハルド
コヘン キャサリン
コヘン キャサリン
バウムガルトル‐ストラスセル ベラ
バウムガルトル‐ストラスセル ベラ
アスペック アンドレアス
アスペック アンドレアス
カイネル マヌエラ
カイネル マヌエラ
ブリム ベルンハルド
ブリム ベルンハルド
キエフマンン ベティナ
キエフマンン ベティナ
ワトソン エリザベス
ワトソン エリザベス
アイストレイトフネル マリオ
アイストレイトフネル マリオ
バイエル カタリナ
バイエル カタリナ
ミュールバッヒャー エルサ
ミュールバッヒャー エルサ
Original Assignee
ホオキパ バイオテック ジーエムビーエイチ
ホオキパ バイオテック ジーエムビーエイチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ホオキパ バイオテック ジーエムビーエイチ, ホオキパ バイオテック ジーエムビーエイチ filed Critical ホオキパ バイオテック ジーエムビーエイチ
Publication of JP2017503482A publication Critical patent/JP2017503482A/ja
Publication of JP2017503482A5 publication Critical patent/JP2017503482A5/ja
Application granted granted Critical
Publication of JP6818551B2 publication Critical patent/JP6818551B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016536893A 2013-12-03 2014-12-03 Ｃｍｖワクチン Active JP6818551B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361911135P 2013-12-03 2013-12-03
US61/911,135 2013-12-03
US201462055699P 2014-09-26 2014-09-26
US62/055,699 2014-09-26
PCT/EP2014/076466 WO2015082570A1 (en) 2013-12-03 2014-12-03 Cmv vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020218641A Division JP7001807B2 (ja) 2013-12-03 2020-12-28 Ｃｍｖワクチン

Publications (3)

Publication Number Publication Date
JP2017503482A JP2017503482A (ja) 2017-02-02
JP2017503482A5 JP2017503482A5 (enExample) 2018-01-18
JP6818551B2 true JP6818551B2 (ja) 2021-01-20

Family

ID=52232138

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016536893A Active JP6818551B2 (ja) 2013-12-03 2014-12-03 Ｃｍｖワクチン
JP2020218641A Active JP7001807B2 (ja) 2013-12-03 2020-12-28 Ｃｍｖワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020218641A Active JP7001807B2 (ja) 2013-12-03 2020-12-28 Ｃｍｖワクチン

Country Status (17)

Country Link
US (3) US10111945B2 (enExample)
EP (2) EP3904522A1 (enExample)
JP (2) JP6818551B2 (enExample)
CN (2) CN105980570B (enExample)
AU (2) AU2014359276B2 (enExample)
CA (1) CA2932318C (enExample)
CY (1) CY1124288T1 (enExample)
DK (1) DK3077519T3 (enExample)
ES (1) ES2868427T3 (enExample)
HR (1) HRP20211015T1 (enExample)
HU (1) HUE054579T2 (enExample)
LT (1) LT3077519T (enExample)
PL (1) PL3077519T3 (enExample)
PT (1) PT3077519T (enExample)
RS (1) RS61993B1 (enExample)
SI (1) SI3077519T1 (enExample)
WO (1) WO2015082570A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2604695T1 (sl) 2007-12-27 2023-03-31 Universitaet Zuerich Prorektorat Forschung Replikacijsko defektni arenavirusni vektorji
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
JP6818551B2 (ja) 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
SI3218504T1 (sl) 2014-11-13 2020-11-30 Universite De Geneve Tri-segmentirani arenavirusi kot vakcinski vektorji
EP3031822A1 (en) * 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
AU2016274655B2 (en) 2015-06-10 2021-06-17 NeoTrail Therapeutics, Inc. HPV vaccines
AU2016342045A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
CA3003557A1 (en) * 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
DK3373959T3 (da) 2015-11-12 2022-09-19 Hookipa Biotech Gmbh Arenaviruspartikler som cancervacciner
WO2017156146A1 (en) * 2016-03-08 2017-09-14 University Of Vermont And State Agricultural College Modified arenavirus
SG11201808426XA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
EP3528821A4 (en) * 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
US20200206334A1 (en) 2016-11-04 2020-07-02 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
US11572389B2 (en) * 2017-01-27 2023-02-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
KR20190139951A (ko) 2017-04-14 2019-12-18 리젠엑스바이오 인크. 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
WO2018204080A1 (en) * 2017-05-02 2018-11-08 The Scripps Research Institute Compositions and methods related to arenavirus immunogens
US12558434B2 (en) 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
CN112512569A (zh) * 2018-05-11 2021-03-16 希望之城 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
CN113271968B (zh) * 2018-10-17 2024-06-14 葛兰素史密丝克莱恩生物有限公司 经修饰的巨细胞病毒蛋白和稳定化的复合物
CA3121915C (en) * 2018-12-10 2025-05-20 Km Biologics Co., Ltd. VACCINE FOR THE PREVENTION OR TREATMENT OF CONGENITAL CYTOMEGALOVIRUS INFECTION
WO2021089853A1 (en) 2019-11-07 2021-05-14 Universität Basel Arenaviruses as vectors
CN115698298A (zh) * 2020-06-09 2023-02-03 Km生物医薬股份公司 巨细胞病毒的gB与五聚体的融合蛋白和包含该融合蛋白的疫苗
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
RU2756557C1 (ru) * 2020-11-02 2021-10-01 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Способ опосредованного определения титра вируса ящура в неинактивированном сырье для вакцины при амплификации вирусной нуклеиновой кислоты и детекции РНК-ампликонов с применением технологии молекулярных биконов
EP4291249A2 (en) 2021-02-10 2023-12-20 RegenxBio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
US20240229073A1 (en) 2021-05-13 2024-07-11 Hookipa Biotech Gmbh Arenaviruses as vectors
WO2024163912A2 (en) * 2023-02-03 2024-08-08 The Children's Medical Center Corporation Vaccine and therapeutic protein delivery compositions comprising fusion proteins
AU2024343172A1 (en) 2023-09-15 2026-03-05 Gilead Sciences, Inc. Arenavirus formulations, methods and uses thereof
CN118221773B (zh) * 2024-02-05 2025-09-09 首都医科大学附属北京儿童医院保定医院 与HLA相关的CMV pp65表位疫苗组合物与应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DE68929478T2 (de) * 1988-01-29 2004-04-29 Aventis Pasteur Rekombinante CMV-Neutralisierungsproteine
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP1265916B1 (en) * 2000-03-21 2005-12-21 Genzyme Corporation Therapeutic anti-cytomegalovirus compounds
DE102004034461B4 (de) * 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
EP1856250B1 (en) * 2005-02-15 2013-07-24 The University of North Carolina At Chapel Hill New live virus vaccines
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
SI2604695T1 (sl) * 2007-12-27 2023-03-31 Universitaet Zuerich Prorektorat Forschung Replikacijsko defektni arenavirusni vektorji
US8580276B2 (en) * 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
WO2010148541A1 (zh) * 2009-06-26 2010-12-29 鑫品生医科技股份有限公司 含衍生自细胞巨大病毒的胜肽的免疫原组成物及使用方法
EP2627352B1 (en) * 2010-10-15 2017-05-10 GlaxoSmithKline Biologicals S.A. Cytomegalovirus gb antigen
EP2661509A2 (en) * 2011-01-07 2013-11-13 Bioscience Slovakia Viral diagnostics
WO2012162428A1 (en) * 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
EP2729165B1 (en) * 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US8834307B2 (en) 2011-10-06 2014-09-16 Kawasaki Jukogyo Kabushiki Kaisha Belt type continuously variable transmission
US20140348863A1 (en) * 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
CA2878344A1 (en) * 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
EP2968506B1 (en) 2013-03-15 2019-07-31 Université de Genève Anti-mycobacterial vaccines
JP6818551B2 (ja) * 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
SI3218504T1 (sl) * 2014-11-13 2020-11-30 Universite De Geneve Tri-segmentirani arenavirusi kot vakcinski vektorji
AU2016274655B2 (en) 2015-06-10 2021-06-17 NeoTrail Therapeutics, Inc. HPV vaccines
CA3003557A1 (en) 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
DK3373959T3 (da) 2015-11-12 2022-09-19 Hookipa Biotech Gmbh Arenaviruspartikler som cancervacciner
IL262963B2 (en) 2016-05-18 2025-01-01 Hookipa Biotech Gmbh Trisegmented PICHINDE viruses as vaccine vectors
US20200206334A1 (en) 2016-11-04 2020-07-02 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
AU2018247958A1 (en) 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
WO2021089853A1 (en) 2019-11-07 2021-05-14 Universität Basel Arenaviruses as vectors
BR112022024404A2 (pt) 2020-05-29 2023-02-07 Hookipa Biotech Gmbh Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus

Also Published As

Publication number Publication date
HRP20211015T1 (hr) 2021-10-01
HUE054579T2 (hu) 2021-09-28
EP3077519A1 (en) 2016-10-12
AU2014359276B2 (en) 2021-01-28
WO2015082570A8 (en) 2015-11-26
JP7001807B2 (ja) 2022-02-04
ES2868427T3 (es) 2021-10-21
WO2015082570A1 (en) 2015-06-11
LT3077519T (lt) 2021-04-26
US11554169B2 (en) 2023-01-17
EP3904522A1 (en) 2021-11-03
EP3077519B1 (en) 2021-03-31
US20230181725A1 (en) 2023-06-15
US20160296619A1 (en) 2016-10-13
CY1124288T1 (el) 2022-07-22
AU2021202541A1 (en) 2021-05-27
DK3077519T3 (en) 2021-06-14
CN115058452A (zh) 2022-09-16
RS61993B1 (sr) 2021-07-30
CN105980570A (zh) 2016-09-28
HK1226440A1 (zh) 2017-09-29
US10111945B2 (en) 2018-10-30
US20190247493A1 (en) 2019-08-15
SI3077519T1 (sl) 2021-07-30
CA2932318A1 (en) 2015-06-11
CA2932318C (en) 2023-10-10
JP2017503482A (ja) 2017-02-02
CN105980570B (zh) 2022-06-07
PL3077519T3 (pl) 2021-10-18
AU2014359276A1 (en) 2016-06-16
PT3077519T (pt) 2021-05-13
JP2021061848A (ja) 2021-04-22

Similar Documents

Publication Publication Date Title
JP7001807B2 (ja) Ｃｍｖワクチン
JP6914950B2 (ja) Ｂ型肝炎ウイルスに対するワクチン
Paillot et al. Equine herpes virus-1: virus, immunity and vaccines
CN107921117B (zh) Hpv疫苗
Kohlmann et al. Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus
JP2003180385A (ja) コロナウイルスに対するワクチン接種用組成物および方法
US20220016234A1 (en) Anti covid-19 therapies using nucleocapsid and spike proteins
WO2023023940A1 (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
US11975063B2 (en) Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use
JP2018517722A (ja) 多価エンテロウイルス（Ｅｎｔｅｒｏｖｉｒｕｓ）ワクチン組成物およびそれに関連する使用
JP7642608B2 (ja) ハンタウイルス抗原性組成物
JP2024502837A (ja) 高病原性コロナウイルスに対する細胞傷害性ｔ細胞免疫療法
HK40063367A (en) Cmv vaccines
HK1226440B (en) Cmv vaccines
CN120442567A (zh) 狂犬病毒糖蛋白嵌合重组水泡性口炎病毒及其应用
TW201026324A (en) HLA-A2-restricted T-cell epitopes of the respiratory syncytial virus fusion protein as peptide-based vaccines
AUPERIN Construction and Evaluation of Recombinant Virus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190423

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20190508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200813

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201228

R150 Certificate of patent or registration of utility model

Ref document number: 6818551

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250